SSD AF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SSD AF (SSD AF).
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
| Metabolism | Silver sulfadiazine is not significantly metabolized; sulfadiazine component undergoes hepatic metabolism via acetylation and glucuronidation. |
| Excretion | Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites. |
| Half-life | Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients. |
| Protein binding | Silver sulfadiazine is highly protein-bound (>95%), primarily to albumin. |
| Volume of Distribution | Not applicable for topical formulation; systemic absorption is minimal (<1%). |
| Bioavailability | Topical: negligible systemic absorption (<1%). |
| Onset of Action | Topical: within 24–48 hours for wound healing; oral: not applicable. |
| Duration of Action | Sustained antimicrobial effect for up to 24 hours after single application; reapplication is required for continued coverage. |
| Molecular Weight | 428.39 |
Apply a thin layer topically once or twice daily to affected area.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment; drug is minimally absorbed systemically. |
| Liver impairment | No dosage adjustment required for hepatic impairment; drug is minimally absorbed systemically. |
| Pediatric use | Apply a thin layer topically once or twice daily; same as adult dosing for ages 2 months and older. |
| Geriatric use | No specific dose adjustment; use same as adult dosing with caution for potential skin fragility. |
| 1st trimester | Avoid use during first trimester due to potential teratogenicity; sulfonamides cross placenta and may cause kernicterus. |
| 2nd trimester | Use only if clearly needed; caution near delivery due to risk of neonatal jaundice and kernicterus. |
| 3rd trimester | Contraindicated in third trimester (especially near term) due to risk of kernicterus in newborn. |
Clinical note
Comprehensive clinical and safety monograph for SSD AF (SSD AF).
| Placental transfer | Sulfadiazine crosses the placenta readily, achieving fetal serum concentrations approximately 50-100% of maternal levels. |
| Breastfeeding | Sulfadiazine is excreted into breast milk. Use with caution in breastfeeding, especially in infants with G6PD deficiency or hyperbilirubinemia. The American Academy of Pediatrics considers silver sulfadiazine compatible with breastfeeding, but monitor for jaundice. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to sulfonamides or silverPregnancy (near term or premature infants)Breastfeeding infants with G6PD deficiency or hyperbilirubinemiaSignificant hepatic or renal impairment
| Precautions | May cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, Use with caution in patients with renal or hepatic impairment, Prolonged use may lead to bacterial resistance, May cause skin discoloration, Potential for sulfonamide-related adverse reactions |
| Food/Dietary | No known food interactions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | SSD AF (silver sulfadiazine) is contraindicated in pregnancy, especially near term, due to risk of kernicterus from sulfonamide component. First trimester: potential for fetal harm based on animal data (cleft palate, skeletal anomalies). Second and third trimesters: sulfonamides cross placenta and may cause neonatal hyperbilirubinemia and kernicterus if used near delivery. |
| Fetal Monitoring | Monitor for signs of kernicterus in neonate if maternal use near term. Assess infant for hemolytic anemia, jaundice, and bilirubin levels if sulfonamide exposure. Monitor maternal renal and hepatic function due to potential sulfonamide toxicity. |
| Fertility Effects | No specific human data on fertility effects. Silver sulfadiazine may cause transient metalloprotein deposition in reproductive tissues; animal studies show no adverse effect on fertility at therapeutic doses. |
| SSD AF (Silver Sulfadiazine 1% cream) is a topical antimicrobial used for burn wound management. Its silver component provides broad-spectrum coverage against gram-negative bacteria, including Pseudomonas aeruginosa. Avoid use on deep or extensive burns (>20% BSA) due to risk of sulfonamide absorption and kernicterus in neonates. Apply in a thin layer (1/16 inch) using sterile technique; debride wound before reapplication. Do not use on pregnant women near term or on infants <2 months. Monitor for argyria with prolonged use. |
| Patient Advice | Apply a thin layer of cream to clean, debrided wound once or twice daily. · Wash hands before and after application; use sterile gloves. · Do not use on face, eyes, or mucous membranes. · Seek medical attention if rash, itching, or skin discoloration occurs. · Store at room temperature; do not freeze. · Avoid prolonged sunlight exposure on treated area due to photosensitivity. |